Intuitive Surgical/$ISRG
1D1W1MYTD1Y5YMAX
Capital at risk
About Intuitive Surgical
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 11,000 da Vinci systems in hospitals worldwide, with more than 6,600 installations in the US and a growing number in emerging markets.
- Ticker
- $ISRG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 17,021
- Headquarters
- Sunnyvale, United States
- Website
- www.intuitive.com
ISRG Metrics
BasicAdvanced
$139B
45.10
$8.72
1.46
-
Price and volume
Market cap
$139B
Beta
1.46
52-week high
$603.88
52-week low
$328.57
Average daily volume
2.5M
Financial strength
Current ratio
6.431
Quick ratio
5.373
Profitability
EBITDA (TTM)
4,180.8
Gross margin (TTM)
66.77%
Net profit margin (TTM)
28.45%
Operating margin (TTM)
31.28%
Effective tax rate (TTM)
17.02%
Revenue per employee (TTM)
$650,000
Management effectiveness
Return on assets (TTM)
10.51%
Return on equity (TTM)
17.42%
Valuation
Price to earnings (TTM)
45.104
Price to revenue (TTM)
12.66
Price to book
7.66
Price to tangible book (TTM)
7.86
Price to free cash flow (TTM)
43.347
Free cash flow yield (TTM)
2.31%
Free cash flow per share (TTM)
9.074
Growth
Revenue change (TTM)
20.66%
Earnings per share change (TTM)
21.65%
3-year revenue growth (CAGR)
18.30%
10-year revenue growth (CAGR)
15.91%
3-year earnings per share growth (CAGR)
29.79%
10-year earnings per share growth (CAGR)
16.11%
What the Analysts think about ISRG
Analyst ratings (Buy, Hold, Sell) for Intuitive Surgical stock.
Analyst projections of the future price of Intuitive Surgical stock.
Bulls say / Bears say
Intuitive delivered a strong second quarter: revenue rose 19% year on year to $2.89 billion, while worldwide da Vinci procedures increased 15%. It also placed 468 da Vinci systems, including 246 newer da Vinci 5 units, showing that demand remains robust despite the slower-growth concerns. (Reuters, GlobeNewswire)
The installed-base model continues to support recurring revenue. Instruments and accessories revenue grew 18% in the second quarter, while Ion procedures rose 36%, giving Intuitive additional growth beyond its core da Vinci platform. (GlobeNewswire, TradingView)
da Vinci 5 is being strengthened as a long-lived platform rather than a one-off product cycle. Intuitive has introduced more than 100 planned updates and is adding Force Feedback instruments in Europe, which could support upgrades, surgeon adoption and higher-value procedures. (Intuitive Surgical Nordics, MassDevice)
US procedure growth slowed to 12% in the second quarter, with weaker demand for deferrable operations as Affordable Care Act subsidy changes affected patient behaviour. HCA’s warning about softer surgical demand and more uninsured patients suggests this may be a wider healthcare-utilisation risk, not just an Intuitive-specific timing issue. (Reuters, TradingView)
China remains a weak spot because local competitors, intense pricing and slower tender activity are weighing on placements. Management has limited visibility on when momentum will improve, while capital constraints in parts of Europe add another risk to system demand. (Ticker Report, Reuters)
Margins remain exposed to trade and input-cost pressure. Intuitive’s 2026 gross-margin guidance already includes a one-percentage-point tariff impact, and the company warns that additional tariffs could materially affect results; the strong second-quarter margin also benefited from a refund of previously paid tariffs. (SEC.gov, Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
ISRG Financial Performance
Revenues and expenses
ISRG Earnings Performance
Company profitability
Upcoming events
No upcoming events
ISRG News
AllArticlesVideos
Funds containing ISRG
AllUSDEURGBP
Fund name | Fund size | $ISRG weighting |
|---|---|---|
iShares Automation & Robotics$RBOT | $5.2B | 2.54% |
iShares Automation & Robotics€2B76 | €4.5B | 2.54% |
iShares Automation & Robotics£RBTX | £3.8B | 2.54% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 2.23% |
iShares AI Adopters and Applications€AIAA | €169M | 1.41% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.